Literature DB >> 26060398

Value of phagocyte function screening for immunotoxicity of nanoparticles in vivo.

Eleonore Fröhlich1.   

Abstract

Nanoparticles (NPs) present in the environment and in consumer products can cause immunotoxic effects. The immune system is very complex, and in vivo studies are the gold standard for evaluation. Due to the increased amount of NPs that are being developed, cellular screening assays to decrease the amount of NPs that have to be tested in vivo are highly needed. Effects on the unspecific immune system, such as effects on phagocytes, might be suitable for screening for immunotoxicity because these cells mediate unspecific and specific immune responses. They are present at epithelial barriers, in the blood, and in almost all organs. This review summarizes the effects of carbon, metal, and metal oxide NPs used in consumer and medical applications (gold, silver, titanium dioxide, silica dioxide, zinc oxide, and carbon nanotubes) and polystyrene NPs on the immune system. Effects in animal exposures through different routes are compared to the effects on isolated phagocytes. In addition, general problems in the testing of NPs, such as unknown exposure doses, as well as interference with assays are mentioned. NPs appear to induce a specific immunotoxic pattern consisting of the induction of inflammation in normal animals and aggravation of pathologies in disease models. The evaluation of particle action on several phagocyte functions in vitro may provide an indication on the potency of the particles to induce immunotoxicity in vivo. In combination with information on realistic exposure levels, in vitro studies on phagocytes may provide useful information on the health risks of NPs.

Entities:  

Keywords:  cytokines; immunotoxicity; nitric oxide generation; phagocytes; phagocytosis; respiratory burst

Mesh:

Substances:

Year:  2015        PMID: 26060398      PMCID: PMC4454219          DOI: 10.2147/IJN.S83068

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


Introduction

Nanoparticles (NPs) are used in many industrial applications and consumer products, and they are also being developed for targeted drug delivery, imaging, and implants in the medical sector. In addition to cytotoxicity, NPs can act on the immune system. Potential immunotoxic effects of NPs are relevant for human health because the immune system is present at all potential portals of entry of NPs and a variety of immunomodulatory actions of NPs has been proposed.1 The immunmodulatory action of a compound usually describes a desired change in the immune system – for instance, for therapeutic intervention – while “immunotoxicity” is used for adverse immunomodulation indicating nondesired effects on the immune system. Immunotoxicity includes interactions with blood (hemolysis, coagulation, and protein binding), accumulation in the mononuclear phagocyte system (MPS), adjuvant properties, binding of haptens, interference with phagocytosis, and modulation of the Th2/Th1 response to antigens. Epidemiological studies in regions with increased concentrations of ultrafine particles suggested that NPs could influence the immune system. High levels of airborne particles caused worsening of asthma and pneumonia in exposed individuals.2–5 Ultrafine particles in the atmosphere do not meet the size requirements of NPs because their upper size limit is usually 2.5 μm, but the reports stimulated further studies on size-related particle effects and raised the awareness that the large surface area of NPs was the reason for their high biological reactivity and toxicity.6 In contrast to cytotoxicity, the role of in vitro immunotoxicity testing is not well established. This is firstly due to general problems in simulating the complexity of the immunological system in vitro, as well as in the extrapolation of in vitro and animal data to human reactions and, secondly, to NP-specific problems. The immune system is redundant and has the capacity to compensate for minor immunotoxicological effects. High interindividual variations of the immune system further complicate the identification of a link between NP exposure and immunotoxicity in humans. Due to the high proliferation rate and compensation capacity of the immune system, only extreme alterations will result in clinical symptoms. On the other hand, decreased immunosurveillance may have long-term consequences, which cannot be directly linked to immunotoxicity. One example of such effects is the three- to fourfold increase in cancer incidence by immunosuppression with cyclosporine A for 5 years.7 Engineered NPs, to which humans might be exposed, comprise titanium dioxide (TiO2) and zinc oxide (ZnO) NPs in consumer products, silver (Ag) NPs in clothing, and silica (SiO2) NPs in food. For medical products, gold (Au), carbon nanotubes (CNTs), and iron oxide are likely candidates. The main exposure routes are dermal for NPs in consumer products and oral for NPs in food and intravenous for NPs in medical use. The exposure of humans to engineered NPs, due to the different use of these products, is expected to be highly variable. Site-specific composition and reaction of the immune system (lung, skin, blood, etc) affords exposure-specific models because the same NPs might cause no immune effects when applied by the oral and dermal route, but they may induce sensitization after intradermal injection.8 This creates a high number of different testing scenarios and renders the testing of all variations in vivo ethically and financially problematic. In this situation, prescreening by in vitro assays, similar to cytotoxicity screening for systemic toxicity, would be helpful. Of course, in vitro testing has the limitation that only one or a few cell types can be evaluated. Data produced after exposure to high doses for a short period are not representative for the exposure to most NPs.9 Furthermore, the protective mechanisms of the body – for instance, mucociliary clearance in the lung and radical scavenging by glutathione in the blood – will mitigate the toxic effect observed in vitro. According to the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), immunotoxicity testing of NPs should focus on macrophages, granulocytes, and dendritic cells (DCs), and the testing should use cytokines as readout parameters.10 Since phagocytes are involved in the unspecific defense, as well as in the specific immune response, impairment of phagocyte function can indicate a decreased reserve of the immune system in NP-exposed individuals. Therefore, phagocytes appear to be suitable for discriminating between NPs interfering or not interfering with the immune system. Several studies report interference with phagocyte function by iron oxide particles, but the iron oxide NPs, which have been approved for medical use (such as Ferumoxtran-10 [Sinerem®]), did not influence the different aspects of phagocyte function. The secretion of proinflammatory cytokines, oxidative burst, phagocytosis, and chemotaxis was not affected by the exposure to the particles in vitro.11 The few studies in which the same NPs were assessed by animal exposure and by exposure of cells to Ag and SiO2 NPs show that impairment of phagocytes function in vitro accords with immune inflammation in vivo.12,13 Proinflammatory action was seen in vivo as well as in macrophages isolated from animals exposed to TiO2 and ZnO NPs.14,15 This review is focused on plain (not pegylated or formulated) metal and metal oxide NPs, such as SiO2, iron oxide, Ag, Au, TiO2, and ZnO NPs, and single-walled CNTs (SWCNTs) and multiwalled CNTs (MWCNTs). These NPs are relevant for humans because they are used in a variety of consumer products and as imaging reagents in medicine. Their classification as non- or low biodegradable NPs is often used to differentiate these particles from the enzymatically degradable NPs, such as liposomes, poly(lactic-co-glycolic acid), dendrimers, and so on, which can cause additional effects by their degradation products. However, it should not be forgotten that metal and metal oxide release ions which can interact with proteins and induce inflammation.16 Nevertheless, the NPs mentioned in this review form a more homogeneous group than nanocarriers for drug delivery, which consist of different materials and possess different surface charges and functionalization. Polystyrene (PS) particles are included in this review because they are often used as model particles for nonbiodegradable NPs.17

Role of phagocytes in the immune system

Professional phagocytes are a group of immune cells that share the feature that they can ingest 0.5–10 μm sized particles better than epithelial cells. Since they are key players in the immune defense, they are represented in almost all organs.18,19 Mononuclear phagocytes are derived from myeloid progenitor cells in bone marrow and develop into granulocytes and monocytes. Monocytes circulate in the blood and differentiate into macrophages (Mφ) in the tissue, where they reside as peritoneal Mφ, alveolar Mφ, mesangial phagocytes of the kidney, synovial type A cells, bone marrow stromal Mφ, splenic red pulp and splenic white pulp Mφ, osteoclasts in the bone, histiocytes in the connective tissue, and as microglia in the brain.20 DCs are a specific lineage of monocytic phagocytes and are mainly present as myeloid and plasmacytoid DCs in the blood, as interstitial DCs in many organs, and as interdigitating DCs in the lymphatic organs. Based on the history of their discovery, some of them received specific names, such as the DCs in the epidermis (Langerhans cells) and Mφs in the liver (Kupffer cells). Phagocytes express different surface markers and differ in their optimum size of phagocytosis. Peritoneal macrophages and monocytes in the peripheral blood optimally phagocytose 0.3–1.1 μm particles. The optimal size for phagocytosis by alveolar macrophages is 3–6 μm particles.21–23 Granulocytes are classified into neutrophilic, eosinophilic, and basophilic granulocytes. The phagocytosis of invading pathogens is the main role of neutrophilic granulocytes. After self-destruction, they are the main component of pus. Compared to neutrophilic granulocytes, eosinophilic and basophilic granulocytes have only a low potential for phagocytosis and act mainly against pathogens by the release of enzymes, as well as toxic and proinflammatory substances. Macrophages possess a variety of receptors for the binding of bacterial constituents (Figure 1). Complement C3b and the Fc fragment of immunoglobulin (Ig)G enable better uptake of opsonized particles. Distinct adhesion molecules, intercellular adhesion molecule (ICAM)-1 (CD54), ICAM-2 (CD102), lymphocyte function-associated antigen (LFA)-1 (CD11a), and LFA-3 (CD58), together with costimulatory molecules B7.1 (CD80), B7.2 (CD86), or CD40, and processed cytosolic proteins presented by major histocompatibility complex (MHC) I or extracellular proteins presented by MHC II, molecules activate T-cells.24 Cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon (IFN)-gamma (IFN-γ), as well as their interaction with lipopolysaccharide (LPS)-binding protein, activate macrophages. Phagocytes ingest a variety of pathogens, such as bacteria, mycobacteria, virus, fungi, and nonpathogenic particles (for instance, dyes and dust) in an unspecific way. On the other hand, they fulfill a definite function as antigen-presenting cells for the correct function of the specific immune system.
Figure 1

Receptors linked to main functions of phagocytes.

Note: Activation of these receptors regulates macrophage function, which can be evaluated by a panel of in vitro assays.

Abbreviations: CD14, lipopolysaccharide-binding protein receptor; LPS, lipopolysaccharide; IFN, interferon; TNF, tumor necrosis factor; MHC, major histocompatibility complex; LFA, lymphocyte function-associated antigen; ICAM, intercellular adhesion molecule; Ig, immunoglobulin; NO, nitric oxide.

In vitro assays to study phagocyte function

A panel of in vitro assays of different complexities can assess phagocyte function. Cytokine secretion, chemotaxis, phagocytosis, and respiratory burst can be measured in all phagocytes. Nitric oxide generation is used only for monocytes and macrophages, whereas the detection of the release of myeloperoxidase and elastase is specific for neutrophilic granulocytes.25 The evaluation of DC function is more complex because it requires interactions with T-cells. Cell isolation, cell exposure, and the detection platform for the performance of the respective assays are described in the core publication and in the supplements of Current Protocols in Immunology.26

Cytokine secretion

A wide spectrum of cytokines is being used in immunotoxicity studies, and phagocytes isolated from exposed animals or cultures of primary cells, and cell lines are equally suitable for these analyses.27 In the presence or absence of the test substance, the release of cytokines/chemokines can be analyzed by enzyme-linked immunosorbant assays, enzyme-linked immunosorbent spot assays, antibody array assays, and bead-based assays. To identify proinflammation responses, interleukin (IL)-1, IL-6, IL-8, and TNF-α are routinely used.28 The classification of allergic responses is based on the type of lymphocyte helper cells that are activated. IL-4 and IL-5 identify TH2 responses, while marker cytokines for TH1 responses are IFN-γ and TNF-β.

Chemotaxis

The migration of leukocytes from an upper chamber across a membrane to a lower chamber containing a chemoattractant is termed chemotaxis. Human serum-derived complement 5a, human lymphocyte-derived chemotactic factor, monocyte chemoattractant protein 1, or N-formyl-methionyl-leucyl-phenylalanine are commonly used attractants.29 All leukocytes are able for chemotaxis, but monocytes, either as primary cells or as cell lines, are used most frequently. In conventional assays, membrane-containing inserts separating the upper from the lower chamber are used. The amount of cells that passed the membrane and reached the lower chamber is counted or quantified by viability assays. Alternatively, an impedance-based system (eg, xCELLigence and ECIS/Taxis) can be used.30,31

Phagocytosis

The phagocytosis assay evaluates the phagocytic activity of fluorescein-labeled bacteria (Staphylococcus aureus, Escherichia coli) in macrophages, monocytes, and polymorphonuclear neutrophils exposed to the test compound.32

Respiratory burst (reactive oxygen production)

This assay can be performed in macrophages, monocytes, and polymorphonuclear neutrophils by the detection of reactive oxygen species (ROS), which is produced upon phagocytosis. For the assays, mostly unlabeled E. coli is used as the phagocytic stimulus. Either chemiluminescent detection by lucigenin or the oxidation of dyes to fluorescent products (eg, rhodamine 123) can be employed for the quantification of the produced oxygen species.33

Nitric oxide (NO) generation

Murine macrophages are routinely used because, when compared to human monocytes, they possess a much higher production of NO.34 An additional advantage of their use is that, in contrast to human macrophages, they do not need a differentiation step. Differentiation of monocytes with the commonly used phorbol 12-myristate 13-acetate or vitamin D3 cannot reproduce the phenotype of human macrophages in vivo, and it introduces additional variations in the assay.35 The common and very reliable detection method of NO uses the Griess reagent.36

Release of elastase and myeloperoxidase

These enzymes are used as indicators for neutrophilic granulocyte activation.37 Assays are performed in whole blood or in neutrophilic granulocytes isolated from peripheral blood. These cells only rarely show direct effects to conventional chemicals, but they are activated by particles.38,39 The relevance of granulocyte activation for immunotoxicity in vivo, however, is currently unclear.

Function of dendritic cells

DCs for testing cannot be obtained directly from the blood in sufficient amounts, but they require differentiation in vitro. CD14+ mononuclear cells isolated from peripheral blood mononuclear cells (PBMCs) are treated with recombinant (rh) granulocyte macrophage colony-stimulating factor and IL-4 for 7 days. Maturation to DCs induced by LPS in the presence and absence of the test compound is verified by the surface expression of CD80, CD83, CD86, and human leukocyte antigen-DR, and by the secretion of IL-12. DC function requires a mixed lymphocyte culture, which analyzes the ability of T-cells to recognize allogenic cells as not belonging to the organism (nonself) as a result of the presence and proliferation of different MHC class II antigens on their surface. This assay is used to identify sensitizing agents. A DC to T-cell ratio of 1:100 is sufficient to initiate vigorous and optimal responses.40 Splenocytes or lymph node cells from treated animals (responder cells) with genetically dissimilar cells (stimulator cells) are cocultured. The assay is usually performed in mice, where cells from another strain can be used as stimulators.41 Stimulator cells are inactivated by irradiation or treatment with a DNA intercalating agent such as mitomycin C. After incubation for several days, proliferation of the responder cells is measured using 3H-thymidine uptake.42 The reaction can also be performed using human PBMC-derived DCs mixed with allogenic lymphocytes,43 and the proliferation of the responder T-cells after contact with allogenic lymphocytes is assessed using a viability (formazan bioreduction) assay. Human myeloid leukemia-derived MUTZ-3 cells have the ability to differentiate into DCs,44 and this assay is in the process of validation as an alternative to the in vivo identification of sensitizing agents.45

Specific issues in the assessment of NPs

The specific nature of NPs, mainly linked to their high surface reactivity, complicates their assessment by in vitro assays. The adsorption of molecules (either bacterial proteins or macromolecules from the body to the particle surface) holds importance for the in vivo and in vitro testing of phagocyte function.

In vivo and in vitro – binding of endotoxin

NPs may bind endotoxin, an LPS and pyrogenic compound of the wall of Gram-negative bacteria. Endotoxin is a strong stimulant of the immune response and causes a pyrogenic reaction in the human body.46 Endotoxin contamination of metal and metal oxide NPs and CNTs is less expected because synthesis often includes steps that kill bacteria. However, contamination is often difficult to exclude because endotoxin can be present in distilled water.47 Due to the strong stimulation of endotoxin, its presence in the sample does not allow for the identification of NP effects. The detection of endotoxin is usually achieved by evaluation in the limulus amebocyte lysate assay, one of the accepted alternatives to the in vivo endotoxin detection assays.48 This assay can be performed in different formats, generally as clotting tests and by colorimetric detection.49 Unfortunately, several NPs interfere with this assay. While for some NPs (TiO2, Ag, CaCO3, SiO2 NPs), interference with the gel-clotting assay was more prominent,50 for other particles (Au NPs), interference with the colorimetric limulus amebocyte lysate assay has been reported.51 The release of inflammatory cytokines (IL-6, IL-8, IL-1) from PBMCs produced variable results and it has been suggested that NPs and endotoxin compete against each other in the induction of cytokines.52

In vivo and in vitro – protein corona

High surface activity leads to the binding of macromolecules to the particle surface once they get into contact with physiological solutions. This coating consists mainly of proteins and has been termed “protein corona”.53 It is hypothesized that the composition of the protein corona determines the trafficking and biological effects of NPs. For a description of the composition and variability of the protein corona, the reader is referred to reviews focusing on this topic.54,55 The physicochemical parameters of the NPs and the composition of the biological fluid are the main factors determining the composition of the protein corona. As a general rule, hydrophobic particles bind more proteins than do hydrophilic particles,56 and abundant proteins in the incubation solution are bound faster on the NP surface than the low abundant proteins.57 Dependence on size and shape, as well as surface charge, has been reported in the following way: Au and SiO2 NPs >10 nm bound more proteins than particles <10 nm; more proteins were attached to TiO2 nanospheres than to nanorods and nanotubes; and binding to positively charged Au, PS, and carbon black particles was higher than to particles without charged groups.58–62 While the composition of the inner coating (hard corona) appeared to be more stable, the composition of the outer part (soft corona) was dynamic and changed in its composition when the particle was transferred from one medium to the other.63 The passage through various media left a fingerprint of the protein composition of the previous media on the NP.64 NPs retained the protein corona during endocytosis; the coat was subsequently removed in lysosomes.65 The role of the protein corona composition for biological effects is still not entirely clear. The reduction of toxic effects, such as cytotoxicity and hemolysis, by protein coating of NPs has been observed in several studies of nonphagocytic cells.66–70 This decreased effect was linked to reduced cellular uptake. Bovine serum albumin (BSA) bound to the surface of carboxyl-functionalized PS, quantum dot (Qdot), and Au NPs decreased cell uptake. The opposite was observed for BSA bound to these types of NPs when they were functionalized with amine groups instead of carboxyl groups.71 All BSA-coated NPs displayed the same effective surface charge, but apparently the BSA structure was influenced by the binding in such a way that different groups were visible for the cells. As a result, BSA-coated carboxylated NPs bound to the albumin receptor, while BSA-coated amine-functionalized NPs were ingested after binding to the cellular scavenger receptor. Protein-coated NPs are expected to produce more pronounced immunological effects because coating with serum increased the uptake by phagocytes.72 The secretion of proinflammatory cytokines by DCs was higher for spherical-than sheet-shaped ZnO NPs, which also bound more proteins on their surface.73 While increased protein binding might have caused the higher secretion of cytokines, the opposite behavior has also been observed: coating of SiO2 NPs with serum decreased cytokine secretion of murine macrophages.74 The presence of complement in the protein corona plays a specific role because the binding of complement C3b and IgG increases uptake by phagocytes by binding to the complement and Fc-receptors. Responses to complement binding were variable; firstly, complement proteins could be activated or inactivated by the binding, and secondly, increased uptake could lead to the activation or inhibition of phagocytes.75,76 Changes in protein conformation appear to be the reason for the different effects; binding of fibrinogen to negatively charged poly(acrylic acid)-conjugated Au NPs induced activation of the Mac-1 receptor on THP-1 monocytes, resulting in a proinflammatory response.77 While these studies support a specific role of the bound proteins, other studies do not support the hypothesis of a protein corona-specific effect because the composition of the protein corona did not correlate with hemocompatibility.78

In vitro – cellular doses

Dose-dependent effects are more difficult to identify for NPs than for conventional compounds because cellular uptake is influenced by the diffusion and sedimentation of the single NPs and agglomerates of the NPs. Several mathematical models have been developed to calculate the deposition of particles suspended in liquids on adherent cells.79,80 Particle-dependent minimal deposition was seen between 50–200 nm, while larger and smaller particles deposited at higher rates.79 Small changes in the dispersion factor caused considerable variations in the deposited dose.80 The differences are due to the formation of agglomerates, but the extent of agglomeration and its effect on deposition are difficult to quantify by mathematical models. The measured deposition of 50–1,000 nm plain PS particles on macrophages increased over time and showed a minimum for 100 nm particles.17 Carboxyl PS particles of 20–1,000 nm showed the cellular uptake of 25%–40% in macrophages with a minimum at 100 nm.81 The cellular dose of the same type of particles with sizes of 20–500 nm in endothelial cells increased from 4.6% to 28.4%, demonstrating higher particle uptake by phagocytic cells, as compared to nonphagocytic cells, in general.82 When adherent cells were cultured upside-down, they ingested much less NPs than the cells cultured in the standard orientation.83 Further complications arise when cells are exposed to aerosolized NPs because cell contact is dependent on the used exposure system, as well as on the variations in the size and concentration of the aerosol; great variations in deposition rates between 0.037% and 30% of the applied dose per well for different particles have been reported.84–88 Furthermore, the influence on flow has to be considered when assessing NP uptake from the systemic blood circulation.89 Endothelial cells best ingested Qdots and SiO2 NPs at a shear stress of 0.05 Pa, which corresponds to postcapillary venules and peripheral arteries.89

In vitro – assay interference

The interference of NPs with several assay systems can strongly influence the results (Table 1). The absorbance of NPs could lead to false-negative results (absence of cytotoxicity is detected, although the NP is cytotoxic) because the metabolic activity (according to absorbance) is estimated to be higher than it actually is.90 Enzyme inhibition by NPs could also cause false-negative results. Lactate dehydrogenase (LDH) is released into the supernatant of cells when the plasma membrane integrity is lost. Its enzymatic activity correlates to the amount of damaged cells. If LDH activity is inhibited by NPs, a lower degree of cell damage will be determined.
Table 1

Mechanisms of interference between nonbiodegradable NPs and in vitro assays

MechanismAssay(s)Particle(s)Reference(s)
AbsorbanceHemolysisAu, C60128130
LALAu, C60131
MTTAu, CB, C60, Qdots, Ag, AgO, iron oxide, SWCNT90, 92, 93, 129, 132136
WST-1Iron oxide137
MTSAl, Qdots51, 97, 138
LDHAu, SiO2, iron oxide, CeO251, 98, 135, 139
Light scatteringMTT, ATPCarbon nanodiamonds140
Dye absorptionMTTSWCNT, CB, Al, iron oxide95, 141144
NRCB, SWCNT, C60, Si, TiO290, 134, 141, 145148
AB, AKSWCNT146
CB, WST-1SWCNT145
Enzyme inactivation/inhibitionLDHCu, Ag149, 150
LDHZnO135
LDHSi, Au, Qdots96
LDHAu151
AKPS105
Enzyme adsorptionLDHCu, Qdots, TiO293, 95, 133, 149, 152, 153
Reduction/enzymatic activityMTTSi, SWCNT, C60, TiO291, 95, 129, 145, 148, 152, 154, 155
ABSi148
AKSWCNT146
Prevention of reductionMTTZn93
OxidationH2DCFCB135
HemoglobinIron oxide128
Protein bindingCytokinesCB, SWCNT, iron oxide, Cu, SiO2, Al2O3, CeO2, NiO2, TiO293, 135, 141, 146, 156159
Increase enzymatic activityLALIron oxide131
HemoglobinPS, SWCNT129, 146
Physical interactionTB, calcein AM, live/deadSWCNT, C60, CB, Qdots90
COMETGe160
Quenching of fluorescenceH2DCFCB, SiO2, SiO2-iron161, 162
LDHCB, SWCNT, C60, Qdots90
Calcein AM/EthD-1CB, SWCNT90
Increase of fluorescenceH2DCFAu, iron oxide, TiO2, C60, SiO2, CB, SWCNT9195
PIQdots, PS95
Calcein AM/EthD-1CB, iron oxide91
ABCB, SWCNT, TiO2, Qdots90, 97, 145
ResazurinCoO51
COMETTiO2, CuO163
Increase of luminescencePhagocytosisQdots130
ATPSiO2139
Quenching of luminescencePhagocytosisAu129, 131
AggregationPlatelet aggregationAu, C60129

Abbreviations: NPs, nanoparticles; Au, gold; C60, C60 fullerenes; LAL, limulus amebocyte lysate; CB, carbon black; Qdots, CdSe quantum dots; Ag, silver; SWCNT, single-walled carbon nanotube; WST-1, water soluble tetrazolium salt; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); Al, aluminum; LDH, lactate dehydrogenase; SiO2, silica; CeO2, cerium oxide; ATP, adenosine triphosphate; NR, neutral red; TiO2, titanium dioxide; AB, alamarBlue; AK, adenylate kinase; Cu, copper; ZnO, zinc oxide; PS, polystyrene; Zn, zinc; H2DCF, dihydrodichlorofluorescein; Al2O2, aluminum oxide; NiO2, nickel oxide; TB, trypan blue; AM, acetoxymethylester; Ge, germanium; EthD-1, ethidium homodimer 1; PI, propidium iodide; CoO, cobalt oxide; CuO, copper (II) oxide.

False-positive results (cytotoxicity is detected although the NP is not toxic) are detected when the fluorescent signals of dihydrofluorescein (the detection of oxidative stress) or of propidium iodide (the disruption of membrane integrity) are enhanced by NPs.91–95 Depending on the assays used, the masking of toxic effects and the identification of nonexistent toxicity by NPs can occur simultaneously. Increased absorbance by colored NPs will result in a higher signal of LDH (indicating more dead cells) and in the MTT assay (indicating more viable cells). The use of multiple assays, therefore, helps to reveal assay interference. The addition of protein, mostly BSA, could prevent interference, but it also could increase it. While false-negative results by the inhibition of LDH activity by Si, Au, and CdSe NPs96 was avoided, the addition of BSA caused false-negative effects in protein detection via the Bradford reagent.97 For the identification of potential assay interference, the incubation of NPs with the assay compounds alone (in the absence of cells) and with cells alone (in the absence of assay compounds) can be used. These controls are, however, only useful when the NPs interact with assay compounds and with the readout; assay interactions by Au NPs, which increased the detected amount of dead cells by shuttling the indicator dye, propidium iodide, into the cells, would not have been revealed.98,99 Similarly, the more global effects of NPs on cultured cells, such as the depletion of nutrients by SWCNTs,100 would go unnoticed. Interference can show dose dependency; dye (acridine) fluorescence is increased by low concentrations of Ag NPs and quenched at high concentrations of NPs.101 Some general rules may help identify and prevent the false interpretation of results. The use of low NP concentrations reduces the problem of interference, but the removal of NPs by centrifugation is generally not recommended because analytes adsorbed to the particles might be removed. Assay interference of the colored CNTs, carbon black, C60 fullerenes, and Au NPs, and of the fluorescent Qdots, may occur more frequently than interference with noncolored Si, SiO2, TiO2, and ZnO NPs. Testing of NPs with several assays based on different detection methods can reduce the risk of misinterpretation.90,102 In this regard, immunotoxicity testing poses more problems than cytotoxicity testing because a lower number of assays for a given immunological function are usually available. On the other hand, compared to cytotoxicity testing, NPs are usually studied at much lower NP concentrations, reducing the risk for interference.

Immunotoxicological data from NP exposure

In vivo exposure includes voluntary inhalation and oral application, forced inhalation (intranasal and intratracheal instillation, oropharyngeal administration), forced oral (intragastric/gavage) application as well as noninvasive dermal and invasive (intradermal injection) dermal applications. Parenteral applications include intravenous and intraperitoneal injection. Table 2 shows the general reaction pattern of the immune system after in vivo exposure to NPs.
Table 2

Effects of NPs after inhal, IN, IG, IP, IV, oral, oroph, and SC application, and ID and IT in normal animals and in animal models (Model)

ParticleSize (nm)ApplicationModelEffectReference(s)
Polystyrene25–50ITLung inflammation164
68ITCoupled antigenStimulation of antigen response165
40IDOVAIncreased sensitization166
58ITOVAIncreased sensitization167
100SCOVAIncreased sensitization168
20, 50, 100IDAtopic dermatitisAggravation of inflammation169
SWCNT1–2OrophDecreased lung clearance of bacteria170
1–2ITProinflammatory cytokine secretion171
1–2ITOVAIncreased sensitization172
1–2Inhal, SCOVAIncreased sensitization113
1–2ITLPSAggravation of inflammation173
DWCNT2INProinflammatory cytokine secretion174
MWCNT20–30SCProinflammatory cytokine secretion175
10–20InhalProinflammatory cytokine secretion176
12.5–25OrophLung inflammation177
20–30ITProinflammatory cytokine secretion178
25IVProinflammatory cytokine secretion179
90IPProinflammatory cytokine secretion180
67ITOVAIncreased sensitization181
10–50Inhal, SCOVAIncreased sensitization113
30–50InhalOVAIncreased sensitization182
67ITLPSAggravation of lung inflammation173
10–50ITLPSAggravation of inflammation183
Ag10IDErythema8
18InhalLung inflammation184
18InhalLung inflammation185
20IVSuppressed immune response to KLH immunization187
22, 42, 71OralIncreased TGF-β levels186
52ITProinflammatory cytokine secretion12
33INOVAIncreased sensitization188
Au50ITLung inflammation189
50, not 10IPProinflammatory cytokine secretion190
21IPAnti-inflammatory action in adipose tissue108
15OrophTDIAggravation of asthma191
5, 15IPIL-1β inflammationDecrease of inflammation109
Iron oxide5.3ITLung inflammation and allergic response193
20IVProinflammatory cytokine secretion194
36ITLung inflammation and cytokine secretion192
58IVDecreased OVA-specific antigen production195, 196
43ITOVAIncreased sensitization197, 198
35ITOVAIncreased sensitization199
SiO210ITLung inflammation200
12IPProinflammatory cytokine secretion13
30, 70IPProinflammatory cytokine secretion201
15IVProinflammatory cytokine secretion202
70IVProinflammatory cytokine secretion203
30, 70, 100IDAtopic dermatitisAggravation of inflammation204
10–20ITOVAIncreased sensitization205
TiO22–5InhalLung inflammation207
5IPProinflammatory cytokine secretion215
5.5IGInfiltration of immune cells in spleen213
8–10INLung inflammation206
20ID, not oralImmune activation8
20InhalLung inflammation208
20ITLung inflammation209
25ITProinflammatory cytokine secretion210
25ITLung inflammation211
15, 28ITLung inflammation212
30–40ITLung inflammation200
66OralProinflammatory cytokine secretion14
20IGProinflammatory and allergic cytokine secretion214
14, 29InhalOVAIncreased sensitization217
15OrophTDIAggravation of asthma191
20IPLPSAggravation of lung inflammation218
28InhalOVAIncreased sensitization216
ZnO10InhalLung inflammation219
<10ITLung inflammation200
21OralNo effect on oral tolerance to OVA107
21IPOVAIncreased sensitization114
55IPOVAIncreased sensitization115

Abbreviations: NPs, nanoparticles; inhal, inhalation; IN, intranasal; IG, intragastral; IP, intraperitoneal; IV, intravenous; oroph, oropharyngeal; SC, subcutaneous; ID, intradermal; IT, intratracheal instillation; OVA, ovalbumin; SWCNT, single-walled carbon nanotube; LPS, lipopolysaccharide; DWCNT, double-walled carbon nanotube; MWCNT, multiwalled carbon nanotube; Ag, silver; TGF, transforming growth factor; KLH, keyhole limpet hemocyanin; Au, gold; TDI, toluene diisocyanate; IL, interleukin; SiO2, silica; TiO2, titanium dioxide; ZnO, zinc oxide.

Systemic immune effects

Effects in the respiratory tract with only a thin epithelium were more pronounced than effects after dermal or oral ingestion exposure, where a horny layer or a thick mucus layer separated NPs from epithelial and immune cells.103 Inflammation in the lung is one of the most frequently reported effects of respiratory exposure to NPs.104 Since cytokines are produced by several cell types, it is not clear whether the reported increases in cytokine secretion and subsequent inflammation were due to specific activation of immune cells, or if they were a consequence of cytotoxic action on alveolar epithelial cells. Heavy metal-containing NPs reacted in a similar manner as PS particles.105,106 Given that heavy metal-containing NPs show ROS generation, and since they are expected to have greater cytotoxicity, the similarity of the reaction does not support the hypothesis of cell death (induced by more cytotoxic heavy metal-containing NPs) as a main inductor of inflammation. Only a few studies have reported the absence of immunological effects, which could be due to restricted access to immune cells.107 The absence of immune effects after the oral ingestion of and exposure to ZnO and TiO2 NPs could be explained by the hindered assessment of the particles to the cells by mucus.8,107 On the other hand, the low reactivity of intraperitoneally applied Au NPs appears to be due to their high biocompatibility given that few studies have reported on the adverse cellular effects of Au NPs.108,109 This statement is supported by a lack of immunological interference in the cellular assays showing no increased cytokine secretion,110,111 and no effect on DC maturation and activation.94,112 When NPs were applied to diseased animals, the pathology of the disease was aggravated. This aggravation was seen in asthma models, as well as in atopic dermatitis (Table 2). Aggravation of asthma is unlikely to be caused by cytotoxicity of the NPs because exposure by the respiratory tract and by other routes (subcutaneous, intraperitoneal), where no direct contact with the alveolar epithelium occurred, caused the same effects.113–115 The mechanisms for amplifying pre-existing pathologies have been proposed through the following mechanisms:116 pre-existing inflammation in the respiratory tubes could be amplified by enhancing the levels of inflammatory factors or humoral immunity. Second, NPs within the size range of <100 nm were able to stimulate and enhance hypersensitivity, which is primarily mediated by Th2 cells.116

In vitro and ex vivo effects

Phagocyte function after in vitro (cells exposed in wells) and ex vivo (cells harvested from exposed animals) exposure is summarized in Table 3. To evaluate the potential of screening in phagocytes, first, data obtained from ex vivo and in vitro studies have to be compared. Second, the similarity of ex vivo and in vitro exposures to in vivo exposure has to be tested. In vitro data on cytokine secretion and chemotaxis corresponded to the respective ex vivo data (Table 3). NPs showed a similar pattern of interference with phagocyte functions; proinflammatory cytokine secretion (mostly IL-6, IL-1β, and TNF-α) and respiratory burst increased, while phagocytosis and chemotaxis decreased. The degranulation of neutrophilic granulocytes has been shown for a few particles.81,117 The influence on DC maturation and function varied markedly between the particles. MWCNTs inhibited maturation, Au and iron oxide showed no prominent effect, and SiO2 and TiO2 activated DCs.94,112,118,119 The different results could be due to the use of different readouts (maturation and activation).
Table 3

Immune effects in isolated phagocytes, either after in vivo treatment with nanoparticles (ex vivo) or by in vitro treatment

ParticleEffects
Ex vivoIn vitro
PolystyreneProinflammatory cytokine secretion81
Increased respiratory burst81
Neutrophilic granulocyte activation81
MWCNTProinflammatory cytokine secretion220
Inhibition of DC maturation118
SWCNTDecreased chemotaxis221
Decreased phagocytosis221
AgProinflammatory cytokine secretion after IT application8Proinflammatory cytokine secretion222224
Proinflammatory cytokine secretion after inhalation225Decreased phagocytosis12
Proinflammatory cytokine secretion after oropharyngeal application226Increased respiratory burst227
Proinflammatory cytokine secretion after oral application186Decreased NO production228
Neutrophilic granulocyte activation117
AuProinflammatory cytokine secretion112,229,230
No increased cytokine secretion110,111
No effect on DC maturation, no activation94,112
Iron oxideProinflammatory cytokine secretion after IT application199,231Proinflammatory cytokine secretion232
Upon LPS challenge, decreased cytokine secretion after IT application233Decreased phagocytosis234
Increased NO production with and without
LPS challenge233,234
No effect on DC maturation94
SiO2Increased NO production after IT application235Proinflammatory cytokine secretion13,236,237
Activation of DC119
TiO2Proinflammatory cytokine secretion after IT application235,238,239Proinflammatory cytokine secretion240
Proinflammatory cytokine secretion after IG application10Decreased chemotaxis241
Decreased phagocytosis12
Increased NO production after IT application235,239Increased respiratory burst242
Decreased chemotaxis after IT application235,239Activation of DC119
ZnODecrease of cytokine secretion after oral application116Proinflammatory cytokine secretion243245
Proinflammatory cytokine secretion after IT application199Decreased chemotaxis241
Proinflammatory cytokine secretion after inhalation11,219Decreased phagocytosis12
Increased respiratory burst246

Abbreviations: MWCNT, multiwalled carbon nanotube; DC, dendritic cells; SWCNT, single-walled carbon nanotube; Ag, silver; IT, intratracheal instillation; NO, nitric oxide; Au, gold; LPS, lipopolysaccharide, SiO2, silica; TiO2, titanium dioxide; IG, intragastral; ZnO, zinc oxide.

The secretion of proinflammatory cytokines was increased by all NPs when applied by in vitro exposure, and after the ex vivo respiratory exposure, to NPs. The lower sensitivity of phagocytes by the oral route was confirmed in an ex vivo study.120

Uptake of NPs by phagocytes

When NPs are coated with proteins in biological fluids, they are well ingested by phagocytes.121 Phagocytosis of NPs by primary cells, cell lines, macrophages, monocytes, and monocyte-derived macrophages indicated accumulation in the MPS and showed a good correlation to the accumulation of particles in the MPS of the spleen and liver in vivo.122 Due to the crucial function of macrophages and DCs in the specific immune response, the accumulation of NPs in the MPS could result in immunotoxicity. The indication of uptake by the MPS or accumulation in lymphatic organs, however, was not correlated to adverse effects on the immune system in vivo or in vitro.81,123 Accumulation in the spleen was only observed for 30 nm Au particles, while adverse effects on the immune system according to increases in relative spleen weight and immune cell numbers were seen for 5 nm, 10 nm, and 60 nm Au particles.123 Small carboxyl PS particles were ingested in much higher numbers than 1,000 nm particles by macrophages.81 While the 1,000 nm large particles induced oxidative burst and cell damage, particles in the size range between 40 nm and 500 nm were taken up without obvious interference with cell viability and function. Taken together, these data suggest that the uptake of NPs may not result in impaired phagocyte function.

Guidelines for sample preparation and exposure

Physiologically relevant testing is based on sample preparation, as well as on the use of dispersant and intended exposure routes. Most NPs form stable solutions in distilled water, which cannot be used for in vitro studies. The presence of ions and protein in the physiological solution leads to NP agglomerates, which may increase in size, but they may also disintegrate. The surface coating of NPs determines their penetration of barriers, cellular uptake, and immune response.124 The Office of Economic Co-operation and Development (OECD) guidelines for sample preparation and dosimetry had advised that dose should be indicated in terms of mass, surface area, and particle number at a minimum.125 To get information on the stability of the dispersion, repeated measurements are recommended with the documentation of agglomeration and ion release. The dispersants should preferentially contain macromolecules that are present in the target tissue. For exposure with aerosols, and in addition to the NP parameters, the mass median aerodynamic diameter and aerosol concentration should be determined. Guidelines for sample preparation for nanoscale TiO2 are already available,126 and existing guidelines for exposure by spontaneous inhalation, oral gavage, and dermal application are applicable for NP exposure. Moreover, the additional effects of intravenous exposure (for instance, behavior in the syringe) have to be considered. Freshly prepared solutions from stock solutions prepared in water, diluted in cell culture medium, and treated by sonification should be added to the cells. In the case that no route-specific surfactants, such as 1,2 dipalmitoyl-sn-glycero-3-phosphocholine for pulmonary exposure, are used, BSA appears to be a good choice because this zwitterionic molecule prevents the binding of protein from the solution.

Conclusion

Due to the complexity of the immune system, in vivo testing will remain the gold standard. However, intraindividual variations in the immune system, as well as its compensatory abilities, are major limitations. As has been observed in environmental studies of airborne particles, individuals with impaired immune function were affected by small particle doses, while no effects were observed in the healthy population.2–5 This overview on a variety of carbon, metal, and metal oxide NPs shows that these particles caused relatively similar patterns of immunotoxicity in vivo, which involved inflammation and immunosuppression in healthy animals and aggravation of the pathology in animals with pre-existing diseases. This suggests that the classification of particles as more or less immunotoxic by in vitro screening might be helpful. The extent to which such screening could lead to valid results was studied by comparing data obtained by in vivo exposure, in vitro testing and in vitro data (Table 4). This analysis showed that the results obtained in cells isolated from NP-exposed animals were similar to the data obtained of cells, which were exposed to NPs in vitro. Secondly, NPs that inhibited phagocyte functions in vitro reacted in an immunotoxic manner in vivo (Tables 2 and 4). The data suggest that the in vitro testing of phagocytes might predict the typical immunotoxicity pattern of NPs in vivo. Cellular assays may also be suitable to identify disease-related alterations in the immune reaction to NPs because comparison between reactions of PBMCs from healthy and allergic donors showed that the cells exhibited disease-related differences upon challenge.118
Table 4

Overview of nanoparticle actions on phagocyte functions

ParticlesCytokine secretion
Chemotaxis
Phagocytosis
Respiratory burst
NO generation
Degranulation
DC maturation
Ex vivoIn vitroEx vivoIn vitroEx vivoIn vitroEx vivoIn vitroEx vivoIn vitroEx vivoIn vitroEx vivoIn vitro
Polystyrene
MWCNT
SWCNT
Ag
Au↑ −
Iron oxide
SiO2
TiO2
ZnO↑ ↓

Notes: Red arrow: increase; black arrow: decrease; –: no change.

Abbreviations: NO, nitric oxide; DC, dendritic cell; MWCNT, multiwalled carbon nanotube; SWCNT, single-walled carbon nanotube; Ag, silver; Au, gold; SiO2, silica; TiO2, titanium dioxide; ZnO, zinc oxide.

Due to the specific composition of the immune system at different portals of entry, exposure-specific coculture models including immune cells could serve as a possibility to assess immunotoxicants in vitro. Alveolar epithelial cells and alveolar macrophages in cocultures released inflammatory cytokines at lower concentrations of TiO2 NPs than did the respective monocultures.127 At the expense of greater complexity, these systems could increase the sensitivity of immunotoxicity in vitro screening and enable exposure-specific testing. However, until a correlation of these findings in these systems to data obtained in humans has been shown, their value remains elusive.
  222 in total

1.  Cancer rates after kidney transplantation.

Authors:  Ulrik Sodemann; Claus Bistrup; Peter Marckmann
Journal:  Dan Med Bull       Date:  2011-12

2.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

3.  Immune responses of BALB/c mice to subcutaneously injected multi-walled carbon nanotubes.

Authors:  Jie Meng; Man Yang; Fumin Jia; Zhen Xu; Hua Kong; Haiyan Xu
Journal:  Nanotoxicology       Date:  2010-11-01       Impact factor: 5.913

4.  Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages.

Authors:  Keiji Hirota; Taizo Hasegawa; Hideyuki Hinata; Fuminori Ito; Hiroyuki Inagawa; Chie Kochi; Gen-Ichiro Soma; Kimiko Makino; Hiroshi Terada
Journal:  J Control Release       Date:  2007-02-01       Impact factor: 9.776

5.  A compact and portable deposition chamber to study nanoparticles in air-exposed tissue.

Authors:  Peter Mertes; Arnaud P Praplan; Lisa Künzi; Josef Dommen; Urs Baltensperger; Marianne Geiser; Ernest Weingartner; Jaroslav Ricka; Martin Fierz; Markus Kalberer
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-02-19       Impact factor: 2.849

6.  In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells.

Authors:  Maria Davoren; Eva Herzog; Alan Casey; Benjamin Cottineau; Gordon Chambers; Hugh J Byrne; Fiona M Lyng
Journal:  Toxicol In Vitro       Date:  2006-10-20       Impact factor: 3.500

7.  Cytotoxicity of nanoparticles independent from oxidative stress.

Authors:  Eleonore Fröhlich; Claudia Samberger; Tatjana Kueznik; Markus Absenger; Eva Roblegg; Andreas Zimmer; Thomas R Pieber
Journal:  J Toxicol Sci       Date:  2009-10       Impact factor: 2.196

8.  Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model.

Authors:  Larissa V Stebounova; Andrea Adamcakova-Dodd; Jong Sung Kim; Heaweon Park; Patrick T O'Shaughnessy; Vicki H Grassian; Peter S Thorne
Journal:  Part Fibre Toxicol       Date:  2011-01-25       Impact factor: 9.400

9.  A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles.

Authors:  Anke Gabriele Lenz; Erwin Karg; Bernd Lentner; Vlad Dittrich; Christina Brandenberger; Barbara Rothen-Rutishauser; Holger Schulz; George A Ferron; Otmar Schmid
Journal:  Part Fibre Toxicol       Date:  2009-12-16       Impact factor: 9.400

10.  Association of asthma symptoms with peak particulate air pollution and effect modification by anti-inflammatory medication use.

Authors:  Ralph J Delfino; Robert S Zeiger; James M Seltzer; Donald H Street; Christine E McLaren
Journal:  Environ Health Perspect       Date:  2002-10       Impact factor: 9.031

View more
  15 in total

1.  Multi-walled carbon nanotubes enhanced fungal colonization and suppressed innate immune response to fungal infection in nematodes.

Authors:  Shumaila Shakoor; Lingmei Sun; Dayong Wang
Journal:  Toxicol Res (Camb)       Date:  2016-01-04       Impact factor: 3.524

2.  Imaging flow cytometry methods for quantitative analysis of label-free crystalline silica particle interactions with immune cells.

Authors:  Bradley Vis; Jonathan J Powell; Rachel E Hewitt
Journal:  AIMS Biophys       Date:  2020-05-26

Review 3.  Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease.

Authors:  Katherine A Roach; Aleksandr B Stefaniak; Jenny R Roberts
Journal:  J Immunotoxicol       Date:  2019-12       Impact factor: 3.000

Review 4.  Effects of engineered nanoparticles on the innate immune system.

Authors:  Yuanchang Liu; Joseph Hardie; Xianzhi Zhang; Vincent M Rotello
Journal:  Semin Immunol       Date:  2017-10-04       Impact factor: 11.130

Review 5.  Phagocytosis in Teleosts. Implications of the New Cells Involved.

Authors:  María Ángeles Esteban; Alberto Cuesta; Elena Chaves-Pozo; José Meseguer
Journal:  Biology (Basel)       Date:  2015-12-04

6.  Imaging flow cytometry assays for quantifying pigment grade titanium dioxide particle internalization and interactions with immune cells in whole blood.

Authors:  Rachel E Hewitt; Bradley Vis; Laetitia C Pele; Nuno Faria; Jonathan J Powell
Journal:  Cytometry A       Date:  2017-09-20       Impact factor: 4.355

Review 7.  Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation.

Authors:  Eleonore Fröhlich
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

8.  The effect of core and lanthanide ion dopants in sodium fluoride-based nanocrystals on phagocytic activity of human blood leukocytes.

Authors:  Bartlomiej Sojka; Aurelia Liskova; Miroslava Kuricova; Mateusz Banski; Jan Misiewicz; Maria Dusinska; Mira Horvathova; Silvia Ilavska; Michaela Szabova; Eva Rollerova; Artur Podhorodecki; Jana Tulinska
Journal:  J Nanopart Res       Date:  2017-02-13       Impact factor: 2.253

Review 9.  Main trends of immune effects triggered by nanomedicines in preclinical studies.

Authors:  Blanka Halamoda-Kenzaoui; Susanne Bremer-Hoffmann
Journal:  Int J Nanomedicine       Date:  2018-09-17

Review 10.  Comparison of conventional and advanced in vitro models in the toxicity testing of nanoparticles.

Authors:  Eleonore Fröhlich
Journal:  Artif Cells Nanomed Biotechnol       Date:  2018-06-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.